NL-019

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameNL-019
Drug Alias NameNL-019NL019NL 019
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Eribulin payload +[4] 
Mechanisms of ActionAnti-NECTIN4Anti-Trop-2Tubulin inhibitors
TargetsNectin-4Tumor-associated calcium signal transducer 2Tubulin
Therapy Area/IndicationsBreast NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNaliean Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNaliean Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A